Division of Gynecologic Oncology, Vincent Department of Obstetrics & Gynecology, and the Department of Hematology/Oncology, Massachusetts General Hospital, the Center for Surgery and Public Health and the Division of Surgical Oncology, Department of Surgery, Brigham and Women's Hospital, and the Division of Breast Surgery, Department of Surgery, Dana-Farber/Brigham and Women's Hospital, Boston, Massachusetts; theDepartment of Gynecologic Oncology & Reproductive Medicine, the University of Texas MD Anderson Cancer Center, Houston, Texas; and the Division of Gynecologic Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians and Surgeons, and the Division of Gynecologic Oncology, New York University Langone Medical Center, New York, New York.

Corresponding author: Alexandra S. Bercow, MD, Division of Gynecologic Oncology, Vincent Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA; email address: [email protected].

Financial Disclosure J. Alejandro Rauh-Hain received payment from Schlesinger and Guidepoint. Sara Bouberhan received payment from ImmunoGen. Eric L. Eisenhauer received payment from Seagan. Christina Minami's institution received funding from the American College of Surgeons, American Society of Clinical Oncology, and the National Institute of Aging. The other authors did not report any potential conflicts of interest.

Presented at the Dana Farber/Harvard Cancer Center Celebration of Early Career Investigators in Cancer Research, January 19, 2022, Boston, Massachusetts; the Academy Health Annual Meeting, June 3–6, 2022, Washington DC; and the New England Association of Gynecologic Oncologists Annual Conference, June 10–12 2022, Newport, Rhode Island.

Each author has confirmed compliance with the journal's requirements for authorship.

Peer reviews and author correspondence are available at https://links.lww.com/AOG/C922.